<div><p>Background</p><p>An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naïve subjects initiating highly active antiretroviral treatment (HAART).</p><p>Methodology/Principal Findings</p><p>To evaluate the pattern of drug resistance mutations (DRMs) found in adults on ART failing first-line HAART [patients with detectable viral load (VL)]. Untreated subjects [Group 1 (G1; n=99)] and 274 treated subjects with variable length of exposure to ARV´s [6–12 months, Group 2 (G2;n=93); 12-24 months, Group 3 (G3;n=81); >24 months (G4;n=100)] were enrolled. Virological and immunological failure (VF and IF) were measured based on viral load (VL) and T...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Background.Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of ant...
An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of H...
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by dec...
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by dec...
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by dec...
Background: With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential ...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Objective: In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 foll...
Background: There are few data on the epidemiology of primary HIV-1 drug resistance after the roll-o...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Abstract To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up sin...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Background.Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of ant...
An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of H...
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by dec...
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by dec...
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by dec...
Background: With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential ...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Objective: In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 foll...
Background: There are few data on the epidemiology of primary HIV-1 drug resistance after the roll-o...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of ...
Abstract To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up sin...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Background.Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of ant...